Belviq Mass Tort Case Leads
Connect with former Belviq and Belviq XR patients diagnosed with cancer after taking the weight-loss drug withdrawn at the FDA's request in February 2020.
Belviq (Lorcaserin) Cancer Litigation
Belviq (lorcaserin) was approved in 2012 for chronic weight management. A required post-marketing safety trial subsequently showed an increased occurrence of cancer among participants taking the drug relative to placebo, and on February 13, 2020 the FDA requested its withdrawal from the U.S. market. Claims against manufacturer Eisai allege that the cancer risk was knowable and inadequately warned. This is a mature, low-volume tort — worth running as a secondary line within a broader multi-tort program rather than as a standalone docket build. Our campaigns identify former patients with documented prescription history and a qualifying diagnosis.
Associated Conditions
- Pancreatic cancer
- Colorectal cancer
- Lung cancer
- Other cancers diagnosed following sustained lorcaserin use
Claimant Eligibility
- Took Belviq or Belviq XR (lorcaserin), generally for several months or longer
- Diagnosed with pancreatic, colorectal, or lung cancer after starting the drug
- Pharmacy records or prescribing physician identifiable
- Diagnosis followed rather than preceded the period of use
- Claim within the applicable state statute of limitations
Why Law Firms Choose Us
Exclusive Leads
Every lead is yours alone. We never resell or share claimant information with competing firms, guaranteeing you first-mover advantage on every case.
Pre-Qualified Claimants
Our intake specialists screen every potential claimant against your specific case criteria before delivery, so your team only speaks with viable cases.
Live Transfer
Qualified claimants are transferred directly to your intake team in real time, maximizing conversion rates and reducing time-to-retainer.
Belviq legal marketing campaigns: how we acquire cases
Belviq case acquisition runs as a multi-channel program, not a single ad buy. Product liability and class action claimants research their condition long before they contact a lawyer, so we meet potential clients at each stage — paid demand capture for people already searching, paid social and traditional media for people who have not yet connected their injury to the litigation, and organic search for the long research tail.
Digital marketing channels
- Google Ads and paid search demand capture
- Meta and paid social prospecting by exposure profile
- Mass tort search engine optimization for the research tail
- OTT and connected TV retargeting
Traditional media channels
- Broadcast and cable TV in qualifying DMAs
- Radio and streaming audio
- Direct response print in occupational verticals
- Earned media and litigation PR support
How the channel mix is built, budgeted, and measured is covered in our mass tort marketing guide. For intake handling once the lead lands, see mass tort intake.
Running a Belviq mass tort marketing campaign
Common questions from law firms about Belviq lawsuit lead generation and campaign management.
- What does a Belviq mass tort marketing campaign include?
- A Belviq mass tort marketing campaign from Mass Tort Marketing Agency covers multi-channel strategy across Meta, Google PPC, OTT and connected TV, traditional media, and mass tort search engine optimization; compliant ad creative; TCPA-verified intake; claimant qualification against your Belviq case criteria; and signed-retainer reporting. Performance is measured on cost per signed retainer, not raw lead volume.
- How do you generate Belviq mass tort case leads?
- Belviq mass tort case leads are generated through paid social and search campaigns aimed at the specific exposure and injury profile of the litigation, supported by organic content that captures claimants already researching their condition. Every lead is a real, consented claimant — we do not buy aggregated lists or resell shared data.
- What do Belviq legal marketing campaigns cost?
- Belviq legal marketing campaigns are quoted and reported on cost per signed retainer (CPSR), so spend ties directly to signed cases rather than lead count. Cost per retainer varies by tort based on claimant prevalence, media competition, and how tight your case criteria are. We scope a per-tort figure before any spend commitment.
- Are Belviq leads exclusive to my firm?
- Yes. Every Belviq lead is delivered to one firm only — never resold, syndicated, or shared with competing firms. Your firm owns the contact data, consent records, and call recordings.
- How are Belviq claimants qualified before delivery?
- Each Belviq claimant is screened against tort-specific facts (exposure windows, injury markers, and state eligibility) and carries a certified TrustedForm or Jornaya consent record — preserving the exact disclosure language shown at submission — before the lead reaches your intake team.
- How fast can a Belviq case acquisition program scale?
- A Belviq mass tort case acquisition program typically moves from scoping to live media inside two weeks, with volume ramped against your docket capacity rather than pushed to a fixed budget. Volume can be scaled up or down by tort month to month as the litigation posture changes.
- Why was Belviq withdrawn from the market?
- On February 13, 2020 the FDA requested that Eisai voluntarily withdraw Belviq and Belviq XR (lorcaserin) from the U.S. market after a required post-marketing safety clinical trial showed an increased occurrence of cancer among trial participants taking the drug compared with placebo. Eisai complied with the request.
- What is the realistic volume on a Belviq campaign?
- Belviq is a low-volume, long-tail tort rather than a primary docket builder. Prescription exposure was limited relative to the mass torts driving current filings, and the withdrawal is now several years old. It is best run as a secondary line inside a multi-tort program — the search demand is cheap and consistent, but it will not fill a docket on its own.
- Who qualifies for a Belviq claim?
- Claimants generally took Belviq or Belviq XR — typically for several months or longer — and were subsequently diagnosed with pancreatic, colorectal, or lung cancer. Pharmacy records or prescriber identification establishing the exposure period materially strengthen the claim.
Get Belviq campaign pricing on a 30-minute call
We will walk your Belviq case criteria, current cost per signed retainer, and the volume your docket can absorb — and tell you plainly if this tort is not a fit right now.
See how every lead is qualified on our mass tort leads page, read the full mass tort marketing guide, or compare providers in our top mass tort marketing firms guide.